

ZOZNAM LITERATÚRY

1. BAK, T. et al. Memory loss, memory regained: neuropsychological findings and neuroimaging in two cases of paraneoplastic limbic encephalitis with radically different outcomes. *Journal of Neurology, Neurosurgery and Psychiatry* [online]. 2001, 71(1), 40–47 [cit. 23.9.2016]. ISSN 1468-330X. Dostupné z: <http://dx.doi.org/10.1136/jnnp.71.1.40>
2. BHIDAYASIRI, R. et al. Anti-NMDA Receptor Encephalitis. *Movement Disorders: A Video Atlas*. New York: Humana Press, 2012, 204–205. ISBN 978-1-60327-425-8.
3. BORONAT, L. et al. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. *Neurology*. 2011, 76(9), 795–800. ISSN 0028-3878.
4. BOROWSKI, K. et al. Seroprevalence of autoantibodies against brain antigens in health and disease. *Annals of Neurology* [online]. 2014, 76(1), 82–94 [cit. 21.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.24189>
5. BUCKLEY et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. *Annals of Neurology* [online]. 2001, 50, 73–78 [cit. 15.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.1097>
6. CASTILLO-GOMEZ, E. et al. The brain as immunoprecipitator of serum autoantibodies against N-methyl-D-aspartate receptor subunit NR1 are no disease indicator. *Annals of Neurology* [online]. 2016, 79(1), 144–151 [cit. 23.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.24232>.
7. CARVALHO, F. et al. Neuropsychiatric symptoms in autoimmune encephalopathies: a clinician's guide. *International Journal of Clinical Neurosciences and Mental Health* [online]. 2014, 1(11) [cit. 20.9.2016]. ISSN 2182-570X. Dostupné z: <http://dx.doi.org/10.21035/ijcnmh.2014.1.11>
8. COYLE, JT. et al. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. *Annals of the New York Academy of Sciences*. 2003, 1003(1), 318–327. ISSN 0077-8923.
9. CHOE, U. et al. A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. *Psychiatry Research* [online]. 2013, 208(2), 194–196 [cit. 17.9.2016]. ISSN 0165-1781. Dostupné z: <http://dx.doi.org/10.1016/j.psychres.2012.09.035>
10. COUTINHO, E. et al. Do neuronal autoantibodies cause psychosis? A neuroimmunological perspective. *Biological Psychiatry*. 2014, 75(4), 269–275. ISSN 0006-3223.
11. DALMAU, J. et al. Clinical analysis of anti-Ma2-associated encephalitis. *Brain* [online]. 2004, 127(8), 1831–1844. [cit. 18.9.2016]. ISSN 1460-2156. Dostupné z: <http://dx.doi.org/10.1093/brain/awh203>
12. DALMAU, J. et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurology*. 2011, 10(1), 63–74. ISSN 1474-4422.
13. DALMAU, J. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurology* [online]. 2008, 7, 1091–1098 [cit. 24.9.2016]. ISSN 1474-4465. Dostupné z: [http://dx.doi.org/10.1016/S1474-4422\(08\)70224-2](http://dx.doi.org/10.1016/S1474-4422(08)70224-2)
14. DRIESEN, NR. et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. *Molecular Psychiatry* [online]. 2013, 18, 1199–1204 [citované 25.9.2016]. ISSN 1476-5578. Dostupné z: <http://dx.doi.org/10.1038/mp.2012.194>
15. FINKE, C. et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. *Annals of Neurology* [online]. 2013, 74, 284–296 [cit. 20.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.23932>
16. FARBER, B. et al. NMDA receptor hypofunction model of psychosis. *Annals of the New York Academy of Sciences*. 2003, 1003(1), 119–30. ISSN 0077-8923
17. FISHER, R. et al. Two Different 18F-FDG Brain PET Metabolic Patterns in Autoimmune Limbic Encephalitis. *Clinical Nuclear Medicine*. 2012, 37(9), 213–218. ISSN 0363-9762.
18. FLORANCE, N.R. et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. *Annals of Neurology* [online]. 2009, 66, 11–18 [cit. 19.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.21756>

19. GOLDSMITH, C. et al. The case for autoimmunity in the etiology of schizophrenia. *Pharmacotherapy* [online]. 2008, 28, 730–741 [cit. 18.9.2016]. ISSN 1875-9114. Dostupné z: <http://dx.doi.org/10.1592/phco.28.6.730>
20. GABILONDO, I. et al. Analysis of relapses in anti-NMDAR encephalitis. *Neurology*. 2011, 77(10), 996–1000. ISSN 0340-5354.
21. GOUGH, J. et al. Electroconvulsive therapy and/or plasmapheresis in autoimmune encephalitis? *World Journal of Clinical Cases* [online]. 2016, 4(8), 223–228 [cit. 23.9.2016]. ISSN 2307-8960. Dostupné z: <http://dx.doi.org/10.12998/wjcc.v4.i8.223>
22. GRAUS, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurology* [online]. 2016, 15(4), 391–404 [cit. 20.9.2016]. ISSN 1474-4465. Dostupné z: [http://dx.doi.org/10.1016/S1474-4422\(15\)00401-9](http://dx.doi.org/10.1016/S1474-4422(15)00401-9)
23. GRAUS, F. et al. Anti-Hu-associated paraneoplastic encephalomyelitis: Neuropsychiatric symptoms in autoimmune encephalopathies analysis of 200 patients. *Brain* [online]. 2001, 124(6), 1138–1148 [cit. 20.9.2016]. ISSN 1460-2156. Dostupné z: <https://www.ncbi.nlm.nih.gov/pubmed/11353730>
24. GRAUS, F. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. *Journal of Neurology, Neurosurgery and Psychiatry* [online]. 2004, 75(8), 1135–1140 [cit. 20.9.2016]. ISSN1468-330X. Dostupné z: <http://dx.doi.org/10.1136/jnnp.2004.038489>
25. GRAUS, F. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. *Journal of Neurology, Neurosurgery and Psychiatry* [online]. 2004, 75(8), 412–416 [cit. 21.9.2016]. ISSN1468-330X. Dostupné z: <http://dx.doi.org/10.1136/jnnp.2003.034447>
26. GRESA-ARRIBAS, N. et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. *Lancet Neurology* [online]. 2014, 13, 167–177 [cit. 25.9.2016]. ISSN 1474-4465. Dostupné z: [http://dx.doi.org/10.1016/S1474-4422\(13\)70282-5](http://dx.doi.org/10.1016/S1474-4422(13)70282-5)
27. GULTEKIN, S. et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. *Brain* [online]. 2000, 123(7), 1481–1494 [cit. 20.9.2016]. ISSN 1460-2156. Dostupné z: <http://dx.doi.org/10.1093/brain/123.7.1481>
28. HACONEN, Y. et al. A clinico-radiological phenotype of voltage-gated potassium channel complex antibody-mediated disorder presenting with seizures and basal ganglia changes. *Developmental Medicine and Child Neurology* [online]. 2012, 54(12), 1157–1159 [cit. 21.9.2016]. ISSN 1469-8749. Dostupné z: <http://dx.doi.org/10.1111/j.1469-8749.2012.04366>
29. HAMMER, C. et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrity. *Molecular Psychiatry* [online]. 2014, 19(10), 1143–1149 [cit. 22.9.2016]. ISSN 1476-5578. Dostupné z: <http://dx.doi.org/10.1038/mp.2013.110>
30. HAUSSLEITER, I.S. et al. Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients. *Schizophrenia Research* [online]. 2012, 140, 258–259 [cit. 23.9.2016]. ISSN 0920-9964. Dostupné z: <http://dx.doi.org/10.1016/j.schres.2012.05.006>
31. HONNORAT, J. et al.: Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. *Journal of Neurology, Neurosurgery and Psychiatry* [online]. 2009, 80(4), 412–416 [cit. 20.9.2016]. ISSN1468-330X. Dostupné z: <http://dx.doi.org/10.1136/jnnp.2007.138016>
32. HUGHES, E.G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. *Journal of Neuroscience* [online]. 2010, 30, 5866–5875 [cit. 26.9.2016]. ISSN 1529-2401. Dostupné z: <http://dx.doi.org/10.1523/JNEUROSCI.0167-10.2010>
33. IIZUKA, T. et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. *Neurology*. 2008, 70(7), 504–511. ISSN 0340-5354.
34. IRANI SR., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. *Brain*. 2010, 133, 2734–2748. ISSN 0006-8950.
35. JAVITT, D.C. Twenty-five years of glutamate in schizophrenia: are we there yet? *Schizophrenia Bulletin* [online]. 2010, 38, 911–913 [cit. 29.9.2016]. ISSN 1745-1701. Dostupné z: <http://dx.doi.org/10.1093/schbul/sbs100>
36. KAPPUSWAMY, S. et al. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series and literature review and future directions. *General Hospital Psychiatry*. 2014, 36, 388–391. ISSN 0163-8349.

37. KAYSER, S. et al. Anti-NMDA receptor encephalitis in psychiatry. *Current Psychiatry Reviews*. 2011, 7(3), 189–193. ISSN 1573-4005.
38. KAYSER, S. et al. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. *JAMA Neurology*. 2013, 70(9), 1133–1139. ISSN 2168-6149.
39. KRÝSL, D. – MARUSIČ, P. Autoimunitní limbické encefalitidy. *Neurologie pro praxi* [online]. 2012, 13(3), 160–164 [cit. 20.9.2016]. ISSN 1803-5280. Dostupné z: <http://www.neurologiepropraxi.cz/pdfs/neu/2012/03/10.pdf>
40. LAI et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. *Lancet Neurology*. 2010, 9(8), 776–785. ISSN 1474-4465.
41. LANCASTER, E. et al. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. *Neurology*. 2011, 77, 179–189. ISSN 0340-5354.
42. LAWN N. et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. *Mayo Clinic Proceedings* [online]. 2003, 78, 1363–1368 [cit. 25.9.2016]. ISSN 0025-6196. Dostupné z: <http://dx.doi.org/10.4065/78.11.1363>
43. MOGHADDAM, B. et al. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology*. 2012, 37(1), 4–15. ISSN 0893-133X.
44. MALTER et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. *Annals of Neurology* [online]. 2010, 67(4), 470–478 [cit. 20.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.21917>
45. MANN, A. et al. A multidisciplinary approach to the treatment of anti-NMDA- receptor antibody encephalitis: a case and review of the literature. *Journal of Neuropsychiatry and Clinical Neurosciences*. 2012, 24(2), 247–254. ISSN 0895-0172.
46. MANTO, M. et al. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. *Orphanet Journal Of Rare Diseases* [online]. 2010, 5, 31 [cit. 23.9.2016]. ISSN 1750-1172. Dostupné z: <http://dx.doi.org/10.1186/1750-1172-5-31>
47. MARQUES, I. et al. Anti-NMDA receptor encephalitis presenting with total insomnia — A case report. *Journal of Neurological Sciences* [online]. 2014, 336(1-2), 276–280 [cit. 22.9.2016]. ISSN 1590-3478. Dostupné z: <http://dx.doi.org/10.1016/j.jns.2013.10.034>
48. MASDEU, J.C. et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. *American Journal of Psychiatry* [online] 2012, 169, 1120–1121 [cit. 21.9.2016]. ISSN 1535-7228. Dostupné z: <http://dx.doi.org/10.1176/appi.ajp.2012.12050646>
49. MATSUMOTO, T. et al. Electroconvulsive therapy can improve psychotic symptoms in anti-NMDA-receptor encephalitis. *Psychiatry and Clinical Neurosciences*. 2012, 66, 242–243. ISSN 1323-1316.
50. PANZER, J.A. et al. Glutamatergic autoencephalitides: an emerging field. *Journal of Neural Transmission* (Vienna) [online]. 2014, 121(8), 957–968 [cit. 24.9.2016]. ISSN 1435-1463. Dostupné z: <http://dx.doi.org/10.1007/s00702-013-1152-4>
51. PEARLMAN, D.M. et al. Meta-analysis of the association between N-methyl-D-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. *Schizophrenia Research*. 2014, 157, 249–258. ISSN 0920-9964.
52. POLLAK, T.A. et al. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. *Psychological Medicine*. 2014, 44, 2475–2487. ISSN 0033-2917.
53. POTVIN, S. et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. *Biological Psychiatry* [online]. 2007, 63 (8), 801–808 [cit. 20.9.2016]. ISSN 0006-3223. Dostupné z: <http://dx.doi.org/10.1016/j.biopsych.2007.09.024>
54. QUARANTA, G. et al. Anti-AMPA-Receptor Encephalitis Presenting as a Rapid-Cycling Bipolar Disorder in a Young Woman with Turner Syndrome. *Case Reports in Psychiatry* [online]. 2015, ID 273192 [cit. 27.9.2016]. ISSN 2090-6838. Dostupné z: <http://dx.doi.org/10.1155/2015/273192>
55. RAMANTHAN, S. et al. Autoimmune encephalitis: Recent updates and emerging challenges. *Journal of Clinical Neuroscience*. 2014, 21, 722–730. ISSN 0967-5868.
56. ROSENTHAL-SIMONS, R. et al. Autoimmune-induced glutamatergic receptor dysfunctions: Conceptual and psychiatric practice implications. *European Neuropsychopharmacology* [online]. 2013, 23(12), 1659–1671 [cit. 23.9.2016]. ISSN 0924-977X. Dostupné z: <http://dx.doi.org/10.1016/j.euroneuro.2013.05.008>

57. SILLEVIS SP. et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. *Journal of Neurology* [online]. 2002, 249(6), 745–753 [cit. 20.9.2016]. ISSN 1432-1459. Dostupné z: <http://dx.doi.org/10.1007/s00415-002-0706-4>
58. SOMERS, K. et al. Voltage-gated potassium channel-complex antibody-associated limbic encephalitis. *Psychosomatics*. 2011, 52(1), 78–81. ISSN 0033-3182.
59. ŠPALEK, P. – MARTINKA, I. – LISÝ, Ľ. Získaná neuromyotónia – autoimunitná kanalopatia (kazuistika). *Neurológia*. 2008, 3: 177–181. ISSN 1335-9592.
60. TITULAER, J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *The Lancet Neurology*. 2013, 12(2), 157–165. ISSN 1474-4422.
61. TSUTSUI, K. et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. *BMC Psychiatry* [online]. 2012, 12, 37 [cit. 18.9.2016]. ISSN 1471-244X. Dostupné z: <http://dx.doi.org/10.1186/1471-244X-12-37>
62. VANHAERENTS, S. et al. Early and persistent 'extreme delta brush' in a patient with anti-NMDA receptor encephalitis. *Epilepsy & Behavior Case Reports* [online]. 2014, 2, 67–70 [cit. 29.9.2016]. ISSN 2213-3233. Dostupné z: <http://dx.doi.org/10.1016/j.ebcr.2014.01.002>
63. VEDELER, A. et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. *European Journal of Neurology* [online]. 2006, 13(7), 682–690 [cit. 20.9.2016]. ISSN 1468-1331. Dostupné z: <http://dx.doi.org/10.1111/j.1468-1331.2006.01266.x>
64. VITALIANI, R. et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. *Annals of Neurology* [online]. 2005, 58, 594–604 [cit. 26.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/ana.20614>
65. WATKINS, CJ. et al. Pei Q, Differential effects of electroconvulsive shock on the glutamate receptor mRNA for NR2A, NR2B and mGluR5b. *Brain Molecular Research*. 1998, 61(1–2), 108–113. ISSN 0166- 4328.
66. WEI, JC. et al. Memantine therapy in a patient with severe anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. *Journal of Neuroimmunology*. 2014, 275 (1–2), 47. ISSN 0165-5728.
67. WHITE, D. et al. Paraneoplastic limbic encephalitis in an elderly patient with small cell lung carcinoma. *Ulster Medical Society Journal* [online]. 2010, 79(1), 22–24 [cit. 20.9.2016]. ISSN 0041-6193. Dostupné z: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938990/>
68. YU, Z. et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. *Annals of Neurology* [online]. 2001, 49(2), 146–154 [cit. 20.9.2016]. ISSN 1531-8249. Dostupné z: <http://dx.doi.org/10.1002/1531-8249>
69. ZANDI, S. et al. Disease-relevant autoantibodies in first episode schizophrenia. *Journal of Neurology*. 2011, 258, 686–688. ISSN 0340-5354.
70. ZULIANI, L. et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. *Journal of Neurology, Neurosurgery and Psychiatry*. 2012, 83(6), 638–645. ISSN 0022-3050.